STOCK TITAN

Opus Genetics, Inc. (IRD) insider files Form 144 to sell 9,475 shares

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

George Magrath filed a notice to sell restricted securities of Opus Genetics, Inc. under SEC Rule 144. The planned sale covers 9,475 shares of common stock through Jefferies LLC, with an aggregate market value of $28,898.75 and approximately 83,000,000 shares of the same class outstanding. The shares derive from vested restricted stock units that vested on January 22, 2026, and the proposed sale date is July 23, 2026. In the prior three months, 9,511 shares of Opus Genetics common stock were sold for $49,647.42.

Positive

  • None.

Negative

  • None.
Shares to be sold 9,475 shares Planned Rule 144 sale of Opus Genetics common stock through Jefferies LLC
Aggregate market value of planned sale $28,898.75 Value of 9,475 Opus Genetics shares to be sold under Rule 144
Shares outstanding 83,000,000 shares Approximate Opus Genetics common shares of the class outstanding
Vested RSU shares 9,475 shares Common shares from vested restricted stock units vested on January 22, 2026
Prior 3-month sales volume 9,511 shares Opus Genetics shares sold during the past three months
Prior 3-month sales value $49,647.42 Total consideration for 9,511 shares sold in the past three months
Proposed sale date 07/23/2026 Proposed date for the Rule 144 sale on Nasdaq
RSU vesting date 01/22/2026 Date the restricted stock units vested into common shares
Form 144 regulatory
"filed a notice to sell restricted securities of Opus Genetics, Inc. under Form 144"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Rule 144 regulatory
"plans to sell 9,475 shares of Opus Genetics common stock under Rule 144"
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Vested Restricted Stock Units financial
"originates from Vested Restricted Stock Units in Opus Genetics, Inc."
aggregate market value financial
"planned sale has an aggregate market value of $28,898.75"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.
common stock financial
"9,475 shares of Opus Genetics common stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

How many Opus Genetics shares is George Magrath planning to sell in this Form 144?

George Magrath plans to sell 9,475 shares of Opus Genetics common stock. These shares come from vested restricted stock units that vested on January 22, 2026, and are to be sold through Jefferies LLC on or after July 23, 2026.

What is the origin and vesting date of the Opus Genetics shares in this Form 144?

The 9,475 shares to be sold originate from vested restricted stock units in Opus Genetics, Inc. These RSUs vested on January 22, 2026, and the resulting common shares are now eligible for resale under Rule 144.

Were any Opus Genetics shares sold in the three months prior to this Form 144 filing?

Yes. In the preceding three months, 9,511 shares of Opus Genetics common stock were sold for a total of $49,647.42. This prior activity is disclosed as part of the Rule 144 reporting requirements for recent sales.

Which broker is handling the planned Rule 144 sale for the Opus Genetics shares?

The planned Rule 144 sale of 9,475 Opus Genetics shares will be handled by Jefferies LLC, located at 520 Madison Ave, New York, NY 10022, with the shares listed for trading on the Nasdaq market.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature